Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial

Medicine & Life Sciences

• Simendan 100%
• Amyotrophic Lateral Sclerosis 71%
• Placebos 45%
• Safety 38%
• Vital Capacity 28%
• Sitting Position 13%
• Headache 11%
• Heart Rate 9%
• Least-Squares Analysis 7%
• Diaphragm 6%
• Respiratory Insufficiency 6%
• Duration of Therapy 6%
• Intention 6%
• Dyspnea 5%
• Capsules 5%
• Oral Administration 5%
• Accidental Falls 5%
• Population 5%
• Research Personnel 4%
• Clinical Studies 4%
• Calcium 4%
• Healthy Volunteers 4%
• Therapeutics 4%
• Survival 3%